CoChat

Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system

Cheong, Taek-Chin, Compagno, Mara, Chiarle, Roberto · 2016 · Nature Communications
Cited by 73

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Applications of the CRISPR-Cas9 system to edit the genome have widely expanded to include DNA gene knock-out, deletions, chromosomal rearrangements, RNA editing and genome-wide screenings. Here we show the application of CRISPR-Cas9 technology to edit the mouse and human immunoglobulin (Ig) genes. By delivering Cas9 and guide-RNA (gRNA) with retro- or lenti-virus to IgM+ mouse B cells and hybridomas, we induce class-switch recombination (CSR) of the IgH chain to the desired subclass. Similarly, we induce CSR in all human B cell lines tested with high efficiency to targeted IgH subclass. Finally, we engineer mouse hybridomas to secrete Fab′ fragments instead of the whole Ig. Our results indicate that Ig genes in mouse and human cells can be edited to obtain any desired IgH switching helpful to study the biology of normal and lymphoma B cells. We also propose applications that could transform the technology of antibody production.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms10934

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 33

  1. Gostissa, M., Alt, F. W. & Chiarle, R. Mechanisms that promote and suppress chromosomal translocations in lymphocytes. Annu. Rev. Immunol. 29, 319–350 (2011). · DOI · Paper page
  2. Jung, D., Giallourakis, C., Mostoslavsky, R. & Alt, F. W. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu. Rev. Immunol. 24, 541–570 (2006). · DOI · Paper page
  3. Stavnezer, J., Guikema, J. E. J. & Schrader, C. E. Mechanism and regulation of class switch recombination. Annu. Rev. Immunol. 26, 261–292 (2008). · DOI · Paper page
  4. Boboila, C., Alt, F. W. & Schwer, B. Classical and alternative end-joining pathways for repair of lymphocyte-specific and general DNA double-strand breaks. Adv. Immunol. 116, 1–49 (2012). · DOI · Paper page
  5. Gostissa, M. et al. IgH class switching exploits a general property of two DNA breaks to be joined in cis over long chromosomal distances. Proc. Natl Acad. Sci. USA 111, 2644–2649 (2014). · DOI · Paper page
  6. Zarrin, A. A. et al. Antibody class switching mediated by yeast endonuclease-generated DNA breaks. Science 315, 377–381 (2007). · DOI · Paper page
  7. Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262–1278 (2014). · DOI · Paper page
  8. Doudna, J. A. & Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014). · DOI · Paper page
  9. O'Connell, M. R. et al. Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature 516, 263–266 (2014). · DOI · Paper page
  10. Choi, P. S. & Meyerson, M. Targeted genomic rearrangements using CRISPR/Cas technology. Nat. Commun. 5, 3728 (2014). · DOI · Paper page
  11. Torres, R. et al. Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system. Nat. Commun. 5, 3964 (2014). · DOI · Paper page
  12. Blasco, R. B. et al. Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. Cell Rep. 9, 1219–1227 (2014). · DOI · Paper page
  13. Chiarle, R. et al. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell 147, 107–119 (2011). · DOI · Paper page
  14. Carter, P. J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6, 343–357 (2006). · DOI · Paper page
  15. Srinivasan, L. et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573–586 (2009). · DOI · Paper page
  16. Kraus, M., Alimzhanov, M. B., Rajewsky, N. & Rajewsky, K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 117, 787–800 (2004). · DOI · Paper page
  17. Young, R. M. & Staudt, L. M. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat. Rev. Drug Discov. 12, 229–243 (2013). · DOI · Paper page
  18. Angulo, I. et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science 342, 866–871 (2013). · DOI · Paper page
  19. Lucas, C. L. et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat. Immunol. 15, 88–97 (2014). · DOI · Paper page
  20. Filpula, D. Antibody engineering and modification technologies. Biomol. Eng. 24, 201–215 (2007). · DOI
  21. Couture, M. L. & Heath, C. A. Relationship between loss of heavy chains and the appearance of nonproducing hybridomas. Biotechnol. Bioeng. 47, 270–275 (1995). · DOI
  22. Alt, F. W., Zhang, Y., Meng, F. L., Guo, C. & Schwer, B. Mechanisms of programmed DNA lesions and genomic instability in the immune system. Cell 152, 417–429 (2013). · DOI · Paper page
  23. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012). · DOI · Paper page
  24. Chiarle, R. Translocations in normal B cells and cancers: insights from new technical approaches. Adv. Immunol. 117, 39–71 (2013). · DOI
  25. Hakim, O. et al. DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes. Nature 484, 69–74 (2012). · DOI · Paper page
  26. Deonarain, M. P., Yahioglu, G., Stamati, I. & Marklew, J. Emerging formats for next-generation antibody drug conjugates. Expert Opin Drug Discov. 10, 463–481 (2015). · DOI
  27. Horiuchi, K. et al. Analysis of somatic hypermutations in the IgM switch region in human B cells. J. Allergy Clin. Immunol. 134, 411–419 (2014). · doi:10.1016/j.jaci.2014.02.043
  28. Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997–1007 (2014). · DOI · Paper page
  29. Gopal, A. K. et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 1008–1018 (2014). · DOI · Paper page
  30. Wilson, W. H. et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat. Med. 21, 922–926 (2015). · DOI · Paper page
  31. Hamadani, M., Balasubramanian, S. & Hari, P. N. Ibrutinib in refractory classic Hodgkin's lymphoma. N. Engl. J. Med. 373, 1381–1382 (2015). · DOI
  32. Fruman, D. A. & Cantley, L. C. Idelalisib--a PI3Kdelta inhibitor for B-cell cancers. N. Engl. J. Med. 370, 1061–1062 (2014). · DOI · Paper page
  33. Byrd, J. C. et al. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med. 374, 323–332 (2015). · DOI · Paper page

Cited by

See all 73

Metadata

Authors
Cheong, T.-C., Compagno, M., & Chiarle, R.
Venue
Nature Communications
Published
2016-03-09
Volume
7
Issue
1
ISSN
2041-1723
Cited by
73
References
7
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system. https://app.cochat.ai/papers/10.1038/ncomms10934
The paper
Cheong, T.-C., Compagno, M., & Chiarle, R. (2016). Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system. Nature Communications. https://doi.org/10.1038/ncomms10934

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.